Brief: Genprex Signs Agreement With New York University Langone Health
28/04/2025 13:17
April 28 (Reuters) - Genprex Inc GNPX.O: GENPREX SIGNS EXCLUSIVE TECHNOLOGY LICENSE AGREEMENT WITH NEW YORK UNIVERSITY LANGONE HEALTH FOR THE TREATMENT OF MESOTHELIOMA Source text: ID:nPn8YqW2a Further company coverage: GNPX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genprex
See all newsBrief: Genprex Announces Collaboration With Roche Diagnostics For Biomarker Assay Validation Studies
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy